CHOP Versus CHOP Plus ESHAP and High-Dose Therapy with Autologous Peripheral Blood Progenitor Cell Transplantation for High-Intermediate-Risk and High-Risk Aggressive Non-Hodgkin's Lymphoma

Clinical Lymphoma

Volumn 1, Issue 3, 2000, Pages 219-225

  Intragumtornchai, Tanin ^a,d   Prayoonwiwat, Wichai ^b   Numbenjapon, Tontanai ^b   Assawametha, Noppadol ^a   O'Charoen, Rutchanee ^c   Swasdikul, Daratana ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b Department of Medicine   (Thailand)

^c National Blood Center   (Thailand)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

CHOP; ESHAP; High dose therapy; Peripheral blood progenitor cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ESAP PROTOCOL; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PREDNISONE; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0034578163     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.n.018     Document Type: Article

References (22)

1. Bolwell B, Goormastic M, Andresen S. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point. Bone Marrow Transplant 1997; 19:443-448.
2. Vose JM, Anderson JR, Kessinger A, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11:1846-1851.
3. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316:1493-1498.
4. Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - a Southwest Oncology Group trial. J Clin Oncol 1998; 16:48-55.
5. Petersen FB, Appelbaum FR, Hill R, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8:638-647.
6. Wheeler C, Strawderman M, Ayash L, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993; 11:1085-1091.
7. Bosly A, Coiffier B, Gisselbrecht C, et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10:1615-1623.
8. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
9. Armitage JO, Dick FR, Corder MP. Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat Rep 1981; 65:413-418.
10. Hubbard SM, Chabner BA, DeVita VT Jr., et al. Histologic progression in non-Hodgkin's lymphoma. Blood 1982; 59:258-264.
11. Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4:1470-1480.
12. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13:140-147.
13. Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol 1993; 11:1985-1989.
14. Trump DL, Mann RB, Phelps R, et al. Richter's syndrome: diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. A report of five cases and review of the literature. Am J Med 1980; 68:539-548.
15. Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15:1587-1594.
16. Yuen AR, Kamel OW, Halpern J, et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995; 13:1726-1733.
17. Schouten HC, Bierman PJ, Vaughan WP, et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989; 74:2579-2584.
18. Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86:3257-3262.
19. Foran JM, Apostolidis J, Papamichael D, et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998; 9:865-869.
20. Friedberg JW, Neuberg D, Gribben JG, et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999; 5:262-268.
21. Williams CD, Goldstone AH, Pearce RM, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14:2454-2464.
22. Buckner CD, Birch R, Weaver CH. The rationale for not routinely purging autologous blood stem cell grafts. Hematology 1998; 3:107-117.